AKRO
Akero Therapeutics Inc
NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY
$54.65
+0.00% today
Updated 2025-12-09
Market cap
$4.50B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.75
Dividend yield
—
52W range
$32 – $57
Volume
2.9M
Akero Therapeutics Inc (AKRO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-30.58%
ROA
-0.23%
Debt/equity
0.00x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $0.00 | $-4.56M | — | — | — |
| 2018 | $0.00 | $-81.71M | — | — | — |
| 2019 | $0.00 | $-43.76M | — | — | — |
| 2020 | $0.00 | $-79.19M | — | — | — |
| 2021 | $0.00 | $-100.74M | — | — | — |
| 2022 | $0.00 | $-112.03M | — | — | — |
| 2023 | $0.00 | $-151.76M | — | — | — |
| 2024 | $0.00 | $-252.06M | — | — | — |
Frequently asked questions
How much free cash flow does AKRO generate?
AKRO produced $-231.11M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is AKRO's balance sheet healthy?
AKRO holds $340.24M in cash and equivalents against $35.30M in long-term debt, on $750.11M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.